biostudies-literatureSeethapathy HClaflin Distinguished Scholars AwardNIDDK NIH HHSNational Institutes of Health507-514https://www.ebi.ac.uk/biostudies/studies/S-EPMC8875461biostudies-literatureUnknown37(3)<h4>Background</h4>Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.<h4>Methods</h4>We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.<h4>Results</h4>A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) expeNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal AssociationClinical features of acute kidney injury in patients receiving dabrafenib and trametinib.PMC8875461K23 DK117014K23 DK 117014NIHReynolds KLLee MDSise MESeethapathy HFadden RMRosales IAEfe OChute DFKaufman HLColvin RBStrohbehn IAJhaveri KDSullivan RJRusibamayila NfalseClinical features of acute kidney injury in patients receiving dabrafenib and trametinib.<h4>Background</h4>Our objective was to characterize the incidence, risk factors and clinical features of acute kidney injury (AKI) in patients receiving dabrafenib and trametinib.<h4>Methods</h4>We performed a retrospective cohort study examining the kidney outcomes of patients in a large healthcare system who received dabrafenib/trametinib between 2010 and 2019. The primary outcome was AKI, defined as a 1.5-fold increase in serum creatinine from baseline within a 12-month study period. AKI severity and etiology was determined for each case by chart review. Logistic regression was used to evaluate baseline predictors of AKI.<h4>Results</h4>A total of 199 patients who received dabrafenib in our healthcare system from 2010 to 2019 were included in the analysis. Forty-two patients (21%) expe2022-01-01T00:00:00Z2022 Feb2026-03-27T16:43:21.944Z2025-04-04T08:57:40.433ZS-EPMC88754613335565910.1093/ndt/gfaa372